With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

Outcomes of psychotic disorders are associated with high personal, familiar, societal and
clinical burden. There is thus an urgent clinical and societal need for improving those …

The goal of this guideline is to improve the quality of care and treatment outcomes for
patients with schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental …

Schizophrenia is the eighth leading cause of disability worldwide in people aged 15–44
years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective …

Background Schizophrenia is a highly heterogeneous disorder, and around a third of
patients are treatment-resistant. The only evidence-based treatment for these patients is …

Background No established treatment algorithm exists for patients with schizophrenia.
Whether switching antipsychotics or early use of clozapine improves outcome in (first …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Although treatment-resistant schizophrenia (TRS) was described 50 years ago 1 and has a
gold standard treatment with clozapine based on well-defined criteria, 2 there is still a matter …

Objective An important clinical question is how many patients with acute schizophrenia do
not respond to antipsychotics despite being treated for adequate time and with an effective …

Determining the optimal antipsychotic target dose in acute phase treatment is of high clinical
relevance. The effect of antipsychotics on negative symptoms should be taken into account …